Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
JUBLPHARMA | NSE
1.45
0.16%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
21/04/2026
906.95
905.50
912.55
903.05
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products contract manufacturing of sterile injectables and non-sterile products active pharmaceutical ingredients and solid dosage formulations as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida India.
View LessSmallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
12.4%1 month
30.3%3 months
32.7%6 months
32.1%33.46
-
3.56
0.67
0.32
27.26
3.32
-
10.09B
141.58B
1.51B
0.41
9.29
7.49K
9.10
1.35
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
71.75
Range1M
117.70
Range3M
212.30
Rel. volume
0.17
Price X volume
30.54M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | APLLTD | Drug Manufacturers-Specialty & Generic | 764.3 | 153.15B | 0.90% | 36.23 | 10.65% |
| Caplin Point Laboratories | CAPLIPOINT | Drug Manufacturers-Specialty & Generic | 1748.8 | 132.93B | -0.31% | 30.77 | 0.09% |
| Concord Biotech Limited | CONCORDBIO | Biotechnology | 1043.7 | 110.21B | -2.13% | 67.34 | 0.64% |
| JUBILANT INGREVIA LTD | JUBLINGREA | Biotechnology | 658.75 | 102.81B | -1.29% | 67.54 | 27.04% |
| Strides Pharma Science Limited | STAR | Drug Manufacturers-Specialty & Generic | 996.95 | 92.49B | 0.05% | n/a | 118.41% |
| PGHL | PGHL | Drug Manufacturers-Specialty & Generic | 5084.3 | 83.85B | -0.03% | 42.84 | 1.78% |
| Blue Jet Healthcare Limited | BLUEJET | Biotechnology | 415.3 | 72.04B | 0.72% | 57.09 | 0.19% |
| Aarti Pharmalabs Limited | AARTIPHARM | Drug Manufacturers-Specialty & Generic | 706.7 | 64.05B | 4.52% | 24.57 | 16.23% |
| FDC Limited | FDC | Drug Manufacturers-Specialty & Generic | 363.8 | 60.03B | 1.07% | 28.02 | 0.98% |
| Supriya Lifescience Limited | SUPRIYA | Biotechnology | 620.75 | 49.78B | 0.15% | 32.96 | 0.67% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vedant Fashions Limited | MANYAVAR | Apparel Retail | 450.85 | 110.28B | 0.48% | 84.26 | 27.74% |
| Vertoz Advertising Limited | VERTOZ | Advertising Agencies | 50.53 | 44.32B | -5.04% | 48.67 | 10.74% |
| Signpost India Limited | SIGNPOST | Advertising Agencies | 271.87 | 15.94B | 0.54% | 30.54 | 80.30% |
| "SAI SILKS (KALAMANDIR) LIMITED " | KALAMANDIR | Apparel Retail | 100.64 | 14.83B | -0.92% | 28.83 | 43.67% |
| V2 Retail Limited | V2RETAIL | Apparel Retail | 197.59 | 7.05B | 3.12% | 120.49 | 191.28% |
| Bhagyanagar India Ltd | BHAGYANGR | Copper | 214.72 | 6.94B | -0.03% | 36.36 | 52.08% |
| Madhav Copper Limited | MCL | Copper | 61 | 1.68B | -1.98% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 93.13 | 1.35B | 1.38% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 74.4 | 829.47M | -0.24% | 50.06 | 4.88% |
| Sagardeep Alloys Limited | SAGARDEEP | Copper | 24 | 416.64M | 0.50% | 58.62 | 43.14% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 27.26 | 24.85 | Par |
| Ent. to Revenue | 3.32 | 11.40 | Cheaper |
| PE Ratio | 33.46 | 51.36 | Cheaper |
| Price to Book | 3.56 | 6.83 | Cheaper |
| Dividend Yield | 0.41 | 0.52 | Poor |
| Std. Deviation (3M) | 32.73 | 42.17 | Lower Risk |
| Debt to Equity | 0.67 | 0.35 | Expensive |
| Debt to Assets | 0.32 | 0.17 | Expensive |
| Market Cap | 141.58B | 290.82B | Emerging |